The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
